Bjorkholm and Silfversward identified prognostic factors for women with granulosa cell tumors of the ovary. These can help identify a woman who may benefit from more aggressive or novel therapies The authors are from Karolinska Hospital in Stockholm, Sweden.
Parameters:
(1) stage of the tumor
(2) diameter in cm
(3) rupture of the tumor (spontaneously or during removal)
(4) nuclear atypia
(5) mitotic rate in most mitotically active area
|
Parameter |
Finding |
Points |
|
stage of the tumor |
Stage I |
0 |
|
|
Stage II, III or IV |
1 |
|
nuclear atypia |
absent |
0 |
|
|
present |
1 |
|
diameter of the tumor |
Stage II, III or IV |
0 |
|
|
Stage I and <= 5 cm diameter |
0 |
|
|
Stage I and > 5 cm diameter |
1 |
|
rupture of the tumor |
Stage II, III or IV |
0 |
|
|
Stage I and unruptured |
0 |
|
|
Stage I and ruptured |
1 |
|
mitotic activity |
Stage I |
0 |
|
|
Stage II-IV and low |
0 |
|
|
Stage II-IV and moderate to marked |
1 |
where:
• The sarcomatoid growth pattern was reported as being associated with a poor prognosis by other authors.
• A Stage IV should have a worse prognosis than a Stage II tumor.
number of poor prognostic features =
= SUM(points for all of the parameters)
Interpretation:
• minimum number of poor prognostic factors: 0
• maximum number of poor prognostic factors: 3
• The presence of multiple poor prognostic risk factors is associated with a worse prognosis.
Specialty: Hematology Oncology, Surgery, general, Obstetrics & Gynecology
ICD-10: ,
